Trending Topic

Brain head human mental idea mind 3D illustration background
8 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

Cognitive impairment is the hallmark symptom of Alzheimer’s disease (AD); however, neuropsychiatric symptoms (NPS), including psychosis, agitation and mood disturbances, are common not only in AD but also in Parkinson’s disease, dementia with Lewy bodies, frontotemporal dementia and vascular dementia.1–5 Psychotic symptoms have been reported to be present in 12–74% of patients with AD, with […]

Tanya Simuni, AD/PD 2021: Results from the Phase 2 MOVES-PD Trial (Part 2)

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Mar 25th 2021

We had the pleasure of speaking with Tanya Simuni (Northwestern University Feinberg School of Medicine, Chicago, IL, USA) to discuss the use of venglustat in the treatment of patients with Parkinson’s Disease, and the Phase 2 MOVES-PD study results.

Part 1 of our discussion can be viewed here.

The abstract entitled ‘Venglustat in Parkinson’s Disease Patients with a GBA Mutation: Results from Part 2 of the Phase 2 MOVES-PD Trial’ was presented at The 15th International Conference for Alzheimer’s & Parkinson’s Diseases (Virtual), March 8-14, 2021.

Questions:

  1. Could you tell us a little about the MOVES-PD clinical trial and its findings? (0:14)
  2. Why do you think the study failed to meet its endpoints, and what can we learn from this failure? (2:38)
  3. Is there a role for venglustat in the future treatment of Parkinson’s disease? (3:27)

Disclosures: Tanya Simuni has served as a consultant for Acadia, Denali, General Electric (GE), Neuroderm, Sanofi, Sinopia, Sunovion, Roche, Takeda, MJFF and Voyager; has served on the advisory board for Acadia, Denali, General Electric (GE), Sunovian, Roche; has served as a member of the scientific advisory board of Neuroderm and Sanofi. Tanya Simuni has received research funding from Biogen, Roche, Neuroderm, Sanofi, Sun Pharma, Amneal, Prevail, UCB, NINDS, MJFF and Parkinson’s Foundation.

Support: Interview and filming supported by Touch Medical Media.

Filmed as a highlight of AD/PD Virtual 2021.

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied

This Functionality is for
Members Only

Explore the latest in medical education and stay current in your field. Create a free account to track your learning.

Close Popup